From crisis to cure: the evolving battle against respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV) has long been a significant cause of respiratory illness, particularly in infants, young children, the elderly, and individuals with chronic medical conditions. Since its identification in 1956, RSV has posed a substantial burden on global healthcare systems, primarily due to its widespread prevalence and the lack of effective long-term immunity following natural infection. Despite the advances in our understanding of RSV’s epidemiology and clinical impact, management has remained largely supportive, with no effective vaccines currently available.

The only antiviral treatment approved for severe RSV cases, Ribavirin, has limited use due to its questionable efficacy, potential toxicity, and high cost. Immunoprophylaxis with the monoclonal antibody palivizumab has been available since 1998, specifically for high-risk infants. However, its application has been restricted by cost concerns and uncertainty regarding optimal use.

Recent years have brought significant advancements in the understanding of RSV at the molecular level, paving the way for the development of more effective treatment and prevention strategies. Innovative antiviral drugs, improved long-acting monoclonal antibodies, and promising vaccine candidates are currently in advanced stages of development. These breakthroughs mark an exciting period in RSV research, offering the potential to drastically reduce the disease burden and improve outcomes for affected populations.

As the field continues to evolve, these new interventions may soon transform the landscape of RSV management, moving from predominantly supportive care to targeted, effective prevention and treatment options.